ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Association between clinical dementia rating and clinical outcomes in Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- A paradigm of the diagnosis and treatment for the whole process of Alzheimer's disease.Annals of medicine · 2026Review
- Robust Extrapolated Semi-Solid Magnetization Transfer Reference Fitting for Quantitative Amide Proton Transfer Imaging at 3 T: Application to Patients With Mild Cognitive Impairment and Mild Dementia.Magnetic resonance in medicine · 2026Article
- Association of cerebrospinal fluid amphiphysin-1 levels with cognition and Alzheimer's disease pathology biomarkers.Frontiers in aging neuroscience · 2026Article
- Artificial Intelligence-Enhanced Multi-Algorithm R Shiny Application for Predictive Modeling and Analytics: Case Study of Alzheimer Disease Diagnostics.JMIR aging · 2025Article
- Multidomain therapy for Alzheimer's disease: a scoping review of cognitive decline trials.Molecular neurodegeneration · 2025Article
- Global Societal Burden of Alzheimer's Disease by Severity: a Targeted Literature Review.Neurology and therapy · 2025Review
- Novel multi-task learning for Alzheimer's stage classification using hippocampal MRI segmentation, feature fusion, and nomogram modeling.European journal of medical research · 2025Article
- Functional Connectome of Superagers Reveals Early Markers of Resilience and Vulnerability to Alzheimer's Disease.bioRxiv : the preprint server for biology · 2025Article
- Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.JAMA · 2025Observational
- Association between depression symptoms and cognitive frailty in chronic kidney disease patients: a cross-sectional study.Frontiers in psychiatry · 2025Article
- Yoga an integrated mind body intervention for improvement in quality of life in individuals with Alzheimer's disease and their caregivers.Frontiers in aging · 2025Article
- Predicting Alzheimer's disease CSF core biomarkers: a multimodal Machine Learning approach.Frontiers in aging neuroscience · 2024Article
- Association between clinical dementia rating and clinical outcomes in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Neurofilament light (NfL) chain levels predict clinical decline in Alzheimer's disease: A systematic review and meta-analysis.Journal of Alzheimer's disease reportsReview
- Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 5 countries.
Funding
Abstract
introductionWe examined associations between the Clinical Dementia Rating Scale (CDR) and function (Functional Assessment Scale [FAS]), neuropsychiatric symptoms (Neuropsychiatric Inventory Questionnaire [NPI-Q]), and cognitive impairment in Alzheimer's disease (AD).
methodsWe used data from the National Alzheimer's Coordinating Center Uniform Data Set and defined cognitively unimpaired and AD stages using CDR-global.
resultsFunctional and neuropsychiatric symptoms occur as early as the mild cognitive impairment (MCI) phase. The adjusted lest square mean FAS (95% confidence interval [CI]) was lowest in cognitively unimpaired (3.88 [3.66, 4.11] to 5.01 [4.76, 5.26]) and higher with more advanced AD (MCI: 8.17 [6.92, 9.43] to 20.87 [19.53, 22.20]; mild: 18.54 [17.57, 19.50] to 28.13 [27.14, 29.12]; moderate: 26.01 [25.31, 26.70] to 29.42 [28.73, 30.10]). FAS and NPI-Q scores increased steeply with MCI (NPI-Q: 5.55 [4.89, 6.20] to 7.11 [6.43, 7.78]) and mild AD dementia (NPI-Q: 6.66 [5.72, 7.60] to 8.32 [7.32, 9.33]). DISCUSSION: CDR-global staged AD by capturing differences in relevant outcomes along AD progression. Highlights: There were strong associations among CDR and the various outcomes relevant to healthcare providers, patients, and their care givers, such as activities of daily living.Overall, activities of daily living, neuropsychiatric symptoms, and cognitive function outcomes deteriorated over time and can be observed in early stages of AD (MCI or mild dementia).Our findings directly inform the current understanding of AD progression and can aid in care planning and benefit assessments of early AD interventions to delay the progression of AD to more advanced stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.